EDISON EQUITY RESEARCH - ATHERSYS
May 05 2015 - 7:30AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ATHERSYS - EARLIER THE BETTER
WITH MULTISTEM
Athersys has reported headline data from its highly anticipated
Phase II study of MultiStem in the semi-acute treatment of
ischaemic stroke. The stem cell therapy demonstrated a favourable
safety profile, although the primary/secondary efficacy endpoints
were not met. While disappointing, a post-hoc analysis indicates
that earlier dosing (≤36 hours post-stroke) with MultiStem may
impart a meaningful clinical benefit. Our fair value is lowered to
$205m ($2.55/share) after a 12-month delay to clinical timelines
with a confirmatory study required to determine the early-treatment
signal.
Athersys is a US biotech company developing MultiStem (allogeneic,
bone marrow-derived stem cells). A Phase II trial with MultiStem in
ischaemic stroke has completed, while further studies in AMI (Phase
II) and ARDS (Phase IIa) are planned.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2024 to May 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From May 2023 to May 2024